drugset / Trial / NCT02023333
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Phase 2
Completed
11 enrolled
Memorial Sloan Kettering Cancer Center
Bayer · collabQueens Cancer Center of Queens Hospital · collabState University of New York - Downstate Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the good and bad effects when regorafenib is used instead of standard combination chemotherapy. It is not known if taking regorafenib versus standard chemotherapy will have better, worse or the same results.
Timeline
- Start
- 2013-12-10
- Primary completion
- 2025-08-26
- Completion
- 2025-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 120 mg | — |